Shots:

• The P-II clinical trial involves evaluating ASP377 (a novel 24 valent MAPS Vaccine) vs Prevnar 13 & Pneumovax 23 in 503 adults aged 65-85yrs. with Streptococcus pneumoniae. The vaccine was developed using Affinivax’s MAPS platform technology
• The results showed that the ASP3772 was well tolerated- induced a robust immune response in 24 pneumococcal serotypes in MAPS vaccine as measured by IgG & OPA & showed an increase in Abs response to the conserved pneumococcal proteins
• ASP3772 has also received FDA’s BTD in adults aged >50 yrs. for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes- based on P-II results

  Ref: Astellas | Image: Financial Times